 Thyroid carcinoma, T.C., is the most common malignancy of endocrine organs. Here, the authors show the ability of human embryonic stem cells, HESCs, to recapitulate the different T.C. histotypes upon specific genomic alterations delivered by CISPR, CAS9 and IdentifyKiss1R and TIMP1 targeting as a therapeutic adjuvant option for undifferentiated T.C.S. This article was authored by Veronica Vesky, Alistado, Chiara Modica, and others.